Drug

Development

What We Do

Zikani has created an innovation engine with its proprietary TURBO-ZM platform, a sophisticated, replicable process that is generating an expanding library of novel small-molecule ribosome modulating agents (RMAs) with immense chemical diversity.

With increased specificity for the human ribosome, the resulting small molecule modulators overcome the functional limitations of known Ribosome Modulations. These fully-synthetic RMAs are thus enabled to directly and specifically address underlying abnormalities in protein synthesis.

Our process enables identification of RMAs that are optimized for disease-level specificity, enhanced bioavailability, and superior long-term safety.